Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study

Sutimlimab in Cold Agglutinin Disease

(2021) Alexander Röth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Complement C1s By Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Efficacy and Safety Results from the Randomized, Placebo-Controlled Phase 3 CADENZA Study

(2021) Alexander Roeth et al.   BLOOD

Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting

(2019) Ulrich Jäger et al.   BLOOD REVIEWS

A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway

(2018) Johann Bartko et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Assessing the reliability of the short form 12 (SF-12) health survey in adults with mental health conditions: a report from the wellness incentive and navigation (WIN) study

(2018) Tianyao Huo et al.   Health and Quality of Life Outcomes

Complement Activation and Inhibition in Autoimmune Hemolytic Anemia: Focus on Cold Agglutinin Disease

(2018) Sigbjørn Berentsen   SEMINARS IN HEMATOLOGY

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial

(2018) Ulrich Jäger et al.   BLOOD

Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS

(2015) R. Cofiell et al.   BLOOD

Qualitative and quantitative validation of the FACIT-fatigue scale in iron deficiency anemia

(2015) Sarah Acaster et al.   Health and Quality of Life Outcomes

Cold agglutinin disease

(2013) P. L. Swiecicki et al.   BLOOD

C1-inhibitor efficiently inhibitsEscherichia coli-induced tissue factor mRNA up-regulation, monocyte tissue factor expression and coagulation activation in human whole blood

(2013) A. Landsem et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation

(2012) Ilene C. Weitz et al.   THROMBOSIS RESEARCH

High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease

(2010) S. Berentsen et al.   BLOOD

Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn’s disease

(2009) G. COTEUR et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Association of fatigue and psychological distress with quality of life in patients with a previous venous thromboembolic event

(2009) Paul Lukas et al.   THROMBOSIS AND HAEMOSTASIS